Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

MLO LABline Daily - Mar 5th, 2024

Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology - The

IJMS, Free Full-Text

HER2 Biomarker in Colon Cancer

New treatment options for metastatic HER2-low breast cancer

An Overview of a Biomarker in Breast Cancer International Journal of Pharmaceutical Investigation

Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review - ScienceDirect

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond - ScienceDirect

Identifying ESR1 Mutations to Determine Resistance in HR+ Metastatic Breast Cancer- Cancer Therapy Advisor

How Common Is Triple-Positive Breast Cancer?

HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort - Modern Pathology

Pathology Report, Pathologist Melbourne, VIC

HER2 expression evolution from HER2-negative primary breast cancer to

Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges - ScienceDirect